secwatch.observer — SEC 8-K summary
======================================

Issuer:     Jasper Therapeutics, Inc. (JSPR)
CIK:        0001788028
Form:       8-K
Filed at:   2023-02-17T23:59:59+00:00
Accession:  0001213900-23-012596
Event type: other_material
Sentiment:  positive
Materiality: 0.75
Item codes: 5.02, 5.03, 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Jasper Therapeutics reports Phase 1 briquilimab data: all 12 patients engrafted; appoints Vishal Kapoor to board
--------------------------------------------------------------------------------

- Appointed Vishal Kapoor to board effective Feb 16, 2023; he is Partner at Avego Management and received option for 109,383 shares at $1.83.
- Phase 1 briquilimab data: 12/12 AML patients achieved neutrophil engraftment at median 19 days; no briquilimab-related SAEs.
- 12 patients at Stanford treated outpatient; all discharged same day (zero inpatient days); mean inpatient stay over first 100 days was 4 days.
- Addition of briquilimab to conditioning regimen does not appear to increase GVHD incidence relative to published rates.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1788028/000121390023012596/0001213900-23-012596-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1788028/000121390023012596/ea173877-8k_jasper.htm
  HTML page:      https://secwatch.observer/filing/0001213900-23-012596

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer